What's small today could become huge in the future. That's especially true in the high-stakes world of biopharmaceutical companies. Three Fool.com contributors identified what they believe could be monster stocks in the making. Here's why these chose Axsome Therapeutics (NASDAQ: AXSM), CRISPR Therapeutics (NASDAQ: CRSP), and Intellia Therapeutics (NASDAQ: NTLA). 

Keith Speights (Axsome Therapeutics): Right now, Axsome Therapeutics' market capitalization stands below $4 billion. But the company has multiple arrows in its quiver. I expect that Axsome will grow much larger if only a few of them hit their mark.

Axsome already has two approved products. Auvelity won U.S. Food and Drug Administration (FDA) approval in August 2022 as a treatment for major depressive disorder (MDD). Axsome also acquired sleep-disorder drug Sunosi from Jazz Pharmaceuticals last year. 

Continue reading

Source Fool.com